A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation

This study is testing two experimental cancer vaccines (TSC-100 and TSC-101) to see if they can prevent relapse after an allogeneic stem cell transplant (receiving stem cells from a donor) in patients with leukemia (AML or ALL) or a pre-leukemia condition called MDS. **You may be eligible if...** - You are 18 or older and have been diagnosed with AML (acute myeloid leukemia), ALL (acute lymphoblastic leukemia), or MDS (myelodysplastic syndrome) - You are planning to undergo an allogeneic stem cell transplant (from a donor) - You carry specific genetic markers (HLA-A*0201 and HA-1 or HA-2 positive genotype) that are needed for the vaccines to work **You may NOT be eligible if...** - You do not carry the required genetic markers for the vaccine - You have uncontrolled active infections - You have significant organ damage that would make transplant too risky - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.